This image depicts a strain of Candida auris cultured in a petri dish at the Centers for Disease Control and Prevention (CDC).
Candida auris is a fungal pathogen that has recently emerged as an important cause for nosocomial infection around the world. It is frequently found to be resistant antifungal medication and can result in prolonged colonization of patients’ skin and contamination of surrounding environments. The likelihood of cross contamination and survival on surfaces can lead to nosocomial outbreaks in hospitals and long-term care facilities.
The Canadian government and the CDC recommend placement of colonized or infected patients in single rooms with routine contact precautions; daily and terminal environmental disinfection with a sporicidal agent, like Nocospray.1
Public Health Ontario’ Provincial Infectious Disease Advisory Committee (PIDAC) in addition to enhanced daily cleaning and disinfection suggest that facilities with access to no-touch disinfection technologies like Nocospray can use these to augment their standard efforts.2
For more information see the related links below
https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2018-44/issue-11-november-1-2018/article-1-candida-auris-management.html
https://www.publichealthontario.ca/-/media/documents/pidac-ipac-candida-auris.pdf?la=en
https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html#disinfection
Nocospray has been tested in Canadian hospitals. Systems like the Nocospray have been shown to improve disinfection outcomes over manual methods.
Sources:
1. Canada communicable diseases report (CCDR): Volume 44-11, November 1, 2018: Healthcare-associated infections and antimicrobial resistance
2. PIDAC Interim Guide for Infection Prevention and Control of Candida auris. January 2019
